Skip to content
Investing

Novo Nordisk Raises Its 2026 Outlook as the Wegovy Pill Takes Off

Novo Nordisk's adjusted operating profit rose 27% to DKK 31.7bn in the third quarter, helped by DKK 5.4bn of Wegovy pill sales, and it now sees 2026 growth of minus 2% to plus 2%.

Novo Nordisk's curved white headquarters building in Bagsværd, Denmark, with a blue Novo Nordisk sign in front.
Photo: Johan Wessman, News Øresund / Wikimedia Commons, CC BY 3.0

Novo Nordisk raised its 2026 outlook on Wednesday after third-quarter adjusted operating profit jumped 27 percent at constant exchange rates to DKK 31.7 billion, driven by DKK 5.4 billion of sales of its new Wegovy pill. The shares rose as much as 6 percent in early trading.

A Clear Beat on Sales and Profit

Net sales in the third quarter came to DKK 79.2 billion, up 4 percent at constant exchange rates and 6 percent as reported. Analysts polled by FactSet had expected DKK 73.6 billion. Adjusted operating profit of DKK 31.7 billion compared with expectations of about DKK 28.6 billion.

Obesity care was the engine, with sales up 22 percent to DKK 26.1 billion. Both regions grew: US sales rose 1 percent and international sales 8 percent.

Novo Nordisk, third quarter 2026

  • DKK 79.2bn net sales, up 4% at constant currencies
  • DKK 31.7bn adjusted operating profit, up 27%
  • DKK 5.4bn Wegovy pill sales

Novo Nordisk: share price, chart and news

Four boxes of Novo Nordisk's Wegovy semaglutide pens in different doses stacked on a pharmacy counter.
Four boxes of Novo Nordisk's Wegovy semaglutide pens in different doses stacked on a pharmacy counter. Photo: Nelson R. de Lima Filho / Wikimedia Commons, CC BY 4.0

Impairments Pull Reported Profit Lower

The headline numbers on a reported basis look weaker. Operating profit fell 9 percent at constant exchange rates to DKK 23.0 billion after DKK 8.7 billion of non-cash impairments, and net profit dropped 16 percent to DKK 16.7 billion.

Two charges explain the gap. Novo wrote down DKK 4.6 billion on ziltivekimab, a heart drug candidate whose late-stage trials missed their main goals, and DKK 4.1 billion on right-sizing its manufacturing network. The first is a reminder of pipeline risk; the second suggests Novo now expects to need less production capacity than it had planned.

Guidance Moves From Decline to Flat

The company now expects adjusted sales and adjusted operating profit to change by between minus 2 and plus 2 percent at constant exchange rates this year, compared with a range of minus 6 to 0 percent before. It also lifted its free cash flow guidance by DKK 15 billion at both ends.

2026 guidancePreviousNew
Adjusted sales growth-6% to 0%-2% to +2%
Adjusted operating profit growth-6% to 0%-2% to +2%
Free cash flowDKK 45bn to 55bnDKK 60bn to 70bn

Free cash flow through September was already DKK 83.8 billion, so the new range implies an outflow of between DKK 13.8 billion and DKK 23.8 billion in the fourth quarter.

The Pills Are Doing the Work

The Wegovy pill, launched in the United States in January, brought in DKK 5.4 billion in the quarter and has passed 8 million US prescriptions since launch. By the end of September it was also on sale in the United Arab Emirates, Britain and Germany, and it has since reached eight markets.

The Ozempic pill, launched in the US in May, is adding to that. Weekly new-to-brand prescriptions are running about 100 percent above the levels of Rybelsus, Novo's older oral diabetes drug, before the launch.

For comparison, Eli Lilly reported $184 million of third-quarter sales for Foundayo, its rival GLP-1 pill. On these numbers Novo has a clear early lead in oral obesity treatment, the segment that has become the main test of whether the company can return to growth after a difficult stretch.

What the Stock Now Has to Prove

The share price reaction reflects relief that the bottom of the guidance range has moved up, and that a product launched this year is already contributing a meaningful slice of sales. European markets were broadly firmer on Wednesday morning, with the Stoxx 600 up 0.44 percent in early trading after the Democrats' sweep of the US midterm elections.

Three issues will shape how far the recovery can go. First, pricing: from 1 January Novo plans to cut the US list price of Wegovy by about half and Ozempic by about 35 percent. The company expects that to weigh on 2027 cash flow and is counting on higher volumes to compensate.

Second, the pipeline. CagriSema, its next obesity drug, is planned for a US launch in early 2027 if approved, while the ziltivekimab write-down shows that not every late-stage bet pays off.

Third, competition. Lilly's oral drug is still small next to the Wegovy pill, but it is now on the market, and Novo's own planned US list-price cuts show how quickly pricing in this class can shift.

Chief executive Mike Doustdar's quarter gives investors evidence that oral drugs can widen the market rather than simply replace injections. Whether that holds once US prices fall in January is the question the next set of results will have to answer.

Sources

Related stories

Business

Novo Nordisk Shares Slump as Investors Shrug Off 2030 Blockbuster Targets

Novo Nordisk targeted more than five blockbusters by 2030 and over DKK 150 billion of pipeline sales in 2035, but its shares fell as much as 9 percent as investors questioned the…

Business

Novo Nordisk Says Early CagriSema Responders Lost 25.4% of Body Weight in 68 Weeks

Novo Nordisk says patients who responded early to its obesity shot CagriSema lost 25.4% of their body weight in 68 weeks, but the post hoc analysis is no guide to treatment yet.

Markets

Meta Soars 12.9% and AMD Hits $1 Trillion as the AI Rally Lifts the Nasdaq 3.3%

Meta rose 12.9% on the week after its Muse assistant topped Apple's app chart, and AMD passed a $1tn market value. The Nasdaq 100 gained 3.25%, while Novo Nordisk fell 10.14% and…

Markets

Novartis Sinks 13.5% on Twin Trial Failures as Brent Breaks $100 and the ECB Hikes

Novartis fell 13.54% in the week to 11 September after two late-stage trial failures, while Brent jumped 8.65% to $104.61 a barrel and the ECB raised rates for the second time this…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…